Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class ITerminatedAug 29, 2018Levothyroxine and LiothyronineFailed Content Uniformity Specifications: Product was manufactured using an adulterated active pharmaceutical ingredient; additionally, lack of process controls and good...Westminster Pharmaceuticals LLC · D-1179-2018Class ITerminatedAug 29, 2018Levothyroxine and LiothyronineFailed Content Uniformity Specifications: Product was manufactured using an adulterated active pharmaceutical ingredient; additionally, lack of process controls and good...Westminster Pharmaceuticals LLC · D-1178-2018Class IICompletedAug 29, 2018Camber PharmaceuticalsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Hetero Labs Limited Unit V · D-1116-2018Class IICompletedAug 29, 2018Camber PharmaceuticalsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Hetero Labs Limited Unit V · D-1115-2018Class IICompletedAug 29, 2018Camber PharmaceuticalsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Hetero Labs Limited Unit V · D-1114-2018Class IICompletedAug 29, 2018Camber PharmaceuticalsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Hetero Labs Limited Unit V · D-1113-2018Class IIITerminatedAug 29, 2018Diltiazem HCl Extended-release CapsulesFailed Impurities/Degradation Specifications; out of specification results for related compound per the manufacturerMylan Institutional, Inc. (d.b.a. UDL Laboratories) · D-1112-2018Class IIOngoingAug 29, 2018Valsartan and Hydrochlorothiazide TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.A-S Medication Solutions LLC. · D-1111-2018Class IIOngoingAug 29, 2018Valsartan and Hydrochlorothiazide TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.A-S Medication Solutions LLC. · D-1110-2018Class IIOngoingAug 29, 2018Valsartan TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.A-S Medication Solutions LLC. · D-1109-2018Class IIOngoingAug 29, 2018Valsartan TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.A-S Medication Solutions LLC. · D-1108-2018Class IITerminatedAug 29, 2018Valsartan Tablets USP 320 mgCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Preferred Pharmaceuticals, Inc · D-1107-2018Class IIITerminatedAug 29, 2018Valsartan Tablets USPIncorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.Jubilant Cadista Pharmaceuticals, Inc. · D-1106-2018Class IIITerminatedAug 29, 2018Valsartan Tablets USPIncorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.Jubilant Cadista Pharmaceuticals, Inc. · D-1105-2018Class IIITerminatedAug 29, 2018Valsartan Tablets USPIncorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.Jubilant Cadista Pharmaceuticals, Inc. · D-1104-2018Class IIITerminatedAug 29, 2018Valsartan Tablets USPIncorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.Jubilant Cadista Pharmaceuticals, Inc. · D-1103-2018Class IITerminatedAug 22, 2018Valsartan 320 mg TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.RemedyRepack Inc. · D-1102-2018Class IITerminatedAug 22, 2018Valsartan 160 mg TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.RemedyRepack Inc. · D-1101-2018Class IITerminatedAug 22, 2018Valsartan 80 mg TabletCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.RemedyRepack Inc. · D-1100-2018Class IIITerminatedAug 22, 2018ContraveDefective Container: Customer complaints of punctures in the bottle.Orexigen Therapeutics, Inc. · D-1099-2018Class IITerminatedAug 22, 2018ValsartanCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Northwind Pharmaceuticals LLC · D-1098-2018Class IITerminatedAug 22, 2018ValsartanCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Northwind Pharmaceuticals LLC · D-1097-2018Class IITerminatedAug 22, 2018Valsartan HCTZCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Northwind Pharmaceuticals LLC · D-1096-2018Class IITerminatedAug 22, 2018ValsartanCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Northwind Pharmaceuticals LLC · D-1095-2018Class IITerminatedAug 22, 2018Papav 300/Phent 5mg/10mLLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1094-2018Class IITerminatedAug 22, 2018P/P/P 0.02/40/2mg/mLLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1093-2018Class IITerminatedAug 22, 2018PRO/PA/PH/AT 18mcg/1.8mg/Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1092-2018Class IITerminatedAug 22, 2018PRASH 12.2mcg/1.22m/19.29Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1091-2018Class IITerminatedAug 22, 2018P/P/P (Prostaglandin/Papaverine/Phentolamine) InjectionLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1090-2018Class IITerminatedAug 22, 2018Acetylcysteine 10% Oph SolutionLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1089-2018Class IITerminatedAug 22, 2018Medroxprogesterone 1% Ophthalmic SolutionLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1088-2018Class IITerminatedAug 22, 2018Vitamin D3 InjectionLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1087-2018Class IITerminatedAug 22, 2018Dehydrated Alcohol SolutionLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1086-2018Class IITerminatedAug 22, 2018Morphine Sulf inhalationLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1085-2018Class IITerminatedAug 22, 2018PR/PA/PHLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1084-2018Class IITerminatedAug 22, 2018Triple PLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1083-2018Class IITerminatedAug 22, 2018Avastin 1.25 mg/0.05 mL prefilled syringeLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1082-2018Class IITerminatedAug 22, 2018DMSO 6.25% Opth SolLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1081-2018Class IITerminatedAug 22, 2018Atropine 0.01% Opth SolutionLack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.Ranier's Compounding Laboratory · D-1080-2018Class IIITerminatedAug 22, 2018Atorvastatin Calcium tabletsFailed Impurities/Degradation Specifications - OOS was observed for ATV Cyclo FP Impurity and Total Degradation Impurities tested at the 18 month stability time point in...Dr. Reddy's Laboratories, Inc. · D-1079-2018

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.